Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors.
Antonella SantoroDepartment of Biosciences, Biotechnology and Environment, University of Bari Aldo Moro, 70125 Bari, Italy.ORCID 0000-0002-6193-2050
Silvia De SantisDepartment of Biosciences, Biotechnology and Environment, University of Bari Aldo Moro, 70125 Bari, Italy.
Ferdinando PalmieriDepartment of Biosciences, Biotechnology and Environment, University of Bari Aldo Moro, 70125 Bari, Italy.
Angelo VozzaDepartment of Biosciences, Biotechnology and Environment, University of Bari Aldo Moro, 70125 Bari, Italy.ORCID 0000-0002-2433-465X
Gennaro AgrimiDepartment of Biosciences, Biotechnology and Environment, University of Bari Aldo Moro, 70125 Bari, Italy.ORCID 0000-0002-5219-4412
Immacolata AndolfoDepartment of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II, 80131 Naples, Italy.
Roberta RussoDepartment of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II, 80131 Naples, Italy.ORCID 0000-0002-3624-7721
Antonio PalazzoDepartment of Biosciences, Biotechnology and Environment, University of Bari Aldo Moro, 70125 Bari, Italy.ORCID 0000-0003-0961-6832
Clelia Tiziana StorlazziDepartment of Biosciences, Biotechnology and Environment, University of Bari Aldo Moro, 70125 Bari, Italy.ORCID 0000-0002-1696-0028
Arianna FerrucciCNR Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies (IBIOM), 70126 Bari, Italy.
Yong Woong JunDepartment of Chemistry, Korea Advanced Institute Science and Technology (KAIST), Daejeon 34141, Republic of Korea.ORCID 0000-0001-9359-1265
Eric T KoolDepartment of Chemistry, Stanford University, Stanford, CA 94305, USA.
Giuseppe FiermonteDepartment of Biosciences, Biotechnology and Environment, University of Bari Aldo Moro, 70125 Bari, Italy.ORCID 0000-0002-6764-9395
Achille IolasconDepartment of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II, 80131 Naples, Italy.ORCID 0000-0002-9558-0356
Eleonora ParadiesCNR Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies (IBIOM), 70126 Bari, Italy.
Carlo Marya Thomas MarobbioDepartment of Biosciences, Biotechnology and Environment, University of Bari Aldo Moro, 70125 Bari, Italy.ORCID 0000-0002-2516-0321
Luigi PalmieriDepartment of Biosciences, Biotechnology and Environment, University of Bari Aldo Moro, 70125 Bari, Italy.ORCID 0000-0002-6503-2922
Funding
Measuring and Modulating Oxidative DNA Damage Surveillance PathwaysR01CA217809 · NCI · STANFORD UNIVERSITY · PI KOOL, ERIC T. · 2017 to 2024
$3.7M
Italian Ministry of Education, Universities, and Research RBSI14LTIS "Molecular and pathogenetic mechanism of congenital sideroblastic anemia associated with the SLC25A38 gene deficiency" to E.P.Ministry of University and Research 2017PAB8EM_005 "Membrane transporters, the doors of cellular metabolism. Investigations of biochemical features structure/function relationships, metabolic regulation and physiopathological aspects by in vitro and in vivo experimental models" to E.P.;NCI NIH HHS R01 CA217809U.S. National Cancer Institute CA217809 to E.T.K.
6 · The paper itself
Abstract
Mutations in the SLC25A38 gene are responsible for the second most common form of congenital sideroblastic anemia (CSA), a severe condition for which no effective treatment exists. We developed and characterized a K562 erythroleukemia cell line with markedly reduced expression of the SLC25A38 protein (A38-low cells). This model successfully recapitulated the main features of CSA, including reduced heme content and mitochondrial respiration, increase in mitochondrial iron, ROS levels and sensitivity to oxidative stress. Notably, our study uncovered a new role for extracellular pyridoxal 5'-phosphate (PLP) and other P2 receptor antagonists in rescuing the altered parameters of A38-low cells (for example, the heme content of the A38-low cells was increased from about 50% to about 80% by the P2 receptor antagonists treatment compared with the value of the controls). These findings suggest that targeting P2 receptors could represent a promising therapeutic approach for SLC25A38-associated CSA.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
P2 Receptor Antagonists Rescue Defective Heme Content in an In Vitro SLC25A38-Associated Congenital Sideroblastic Anemia Cell Model. · full record | Socratic